Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.29Walpar Nutritions Ltd demonstrates a mixed financial performance. The company exhibits strengths in solvency, growth, and profitability, particularly in operating profit, EPS, asset growth, ROCE, and ROA. Its equity and debt management are also noteworthy. However, the company faces challenges in liquidity, efficiency, and certain financial metrics, including revenue growth, gross profit margin, and earnings per share. The company's interest coverage is reasonable, providing some financial flexibility. Overall, Walpar Nutritions shows potential for future growth, but it needs to address its liquidity and efficiency issues to ensure long-term stability and success.
Health Score : 5.29Walpar Nutritions Ltd demonstrates a mixed financial performance. The company exhibits strengths in solvency, growth, and profitability, particularly in operating profit, EPS, asset growth, ROCE, and ROA. Its equity and debt management are also noteworthy. However, the company faces challenges in liquidity, efficiency, and certain financial metrics, including revenue growth, gross profit margin, and earnings per share. The company's interest coverage is reasonable, providing some financial flexibility. Overall, Walpar Nutritions shows potential for future growth, but it needs to address its liquidity and efficiency issues to ensure long-term stability and success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
12.44
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
9.89
P/B RATIO
1.29
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.30
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
4.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹26 as on Sep 1, 2026.
Growth Score : 6.00The company has shown strong growth in operating profit, EPS, and assets. The company's revenue growth and net income growth needs improvement. Strong growth in these areas provides a positive outlook for the company's future performance and market position.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 340.86 | 31.32 | 77.92 | 14.78 | 9.8 |
| Operating Profit Growth Rate | 121.74 | 242.16 | 36.1 | 20.42 | 16.43 |
| Earnings Per Share (EPS) Growth | 90.91 | 54.76 | 158.46 | 47.02 | 6.48 |
| Asset Growth Rate | 56.06 | 22.11 | 8.34 | 27.53 | 39.42 |
| Net Income Growth Rate | 140 | 125 | 139.51 | 43.81 | 7.53 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Walpar Nutritions Ltd is an Indian company engaged in the manufacturing, marketing, and distribution of nutraceutical products, dietary supplements, and health-related formulations. It focuses on providing a diverse range of wellness products through its manufacturing facility and established distribution network across India.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Walpar Nutritions Ltd's P/E ratio (TTM) is 12.44, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Walpar Nutritions Ltd's P/B ratio is 1.29, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Walpar Nutritions Ltd's P/S ratio is 0.30, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Walpar Nutritions Ltd's PEG ratio is 1.20.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Walpar Nutritions Ltd's EV/EBITDA ratio is 4.00.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Walpar Nutritions Ltd's ROE is 15.87%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Walpar Nutritions Ltd's ROA is 10.08%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Walpar Nutritions Ltd's ROCE is 14.84%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Walpar Nutritions Ltd's operating margin is 8.45%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Walpar Nutritions Ltd's net margin is 3.81%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Walpar Nutritions Ltd's current ratio is 1.33.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Walpar Nutritions Ltd's debt-to-equity ratio is 0.47.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Walpar Nutritions Ltd's interest coverage ratio is 6.12.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Walpar Nutritions Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Walpar Nutritions Ltd's EPS is 6.48.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹26. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005
Headquarters: Ahmedabad, Gujarat
Core Offerings: Nutraceutical products, Dietary supplements, Ayurvedic formulations, Health food products
Stock Listing: NSE (WALPAR), BSE ({bse})
Promoter: Mr. Chetan Vallabhdas Gandhi, Mr. Manish Vallabhdas Gandhi, Mr. Bharat Vallabhdas Gandhi (Gandhi Family Group)
Walpar Nutritions Ltd was incorporated in 2005, initially focusing on the manufacturing and marketing of nutraceuticals and dietary supplements. Over the years, the company expanded its product portfolio and strengthened its distribution channels within the Indian market. In September 2023, Walpar Nutritions Ltd successfully completed its Initial Public Offering (IPO) and was listed on the NSE Emerge platform, marking a significant milestone in its corporate journey.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Nutraceuticals & Dietary Supplements | 100% | Not publicly disclosed |
Nutraceuticals & Dietary Supplements: The primary business segment involves the manufacturing, marketing, and distribution of a wide array of health and wellness products, including vitamins, minerals, herbal extracts, and protein supplements.
Contract Manufacturing: The company also undertakes contract manufacturing for other brands, leveraging its production capabilities.
Mr. Chetan Vallabhdas Gandhi: Chairman & Managing Director. A co-founder and instrumental in guiding the company's strategic vision, product development, and overall business growth since its inception. Mr. Manish Vallabhdas Gandhi: Whole-time Director. Plays a crucial role in the company's operational management and expansion initiatives.
No major subsidiaries reported.
SME IPO on NSE Emerge in September 2023. No other major recent corporate actions on record.
The Walpar Nutritions Ltd share price today is ₹26 on NSE (WALPAR), as of 26 Sept 2026.
As of 26 Sept 2026, Walpar Nutritions Ltd share price is ₹26, with previous close ₹26. Today's range is ₹26 to ₹26. The 52-week range is ₹21.25 to ₹50.60.
As of today, Walpar Nutritions Ltd's market cap is ₹23.66 crore (Small Cap).
Walpar Nutritions Ltd's current P/E ratio is 12.44, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Walpar Nutritions Ltd's current P/B ratio is 1.29.
Walpar Nutritions Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Walpar Nutritions Ltd's EPS (TTM) is ₹6.48.
Walpar Nutritions Ltd is an Indian company engaged in the manufacturing, marketing, and distribution of nutraceutical products, dietary supplements, and health-related formulations. It focuses on providing a diverse range of wellness products through its manufacturing facility and established distribution network across India.
Walpar Nutritions Ltd is promoted by Mr. Chetan Vallabhdas Gandhi, Mr. Manish Vallabhdas Gandhi, Mr. Bharat Vallabhdas Gandhi (Gandhi Family Group), holding 68.82% as of 26 Sept 2026.
Walpar Nutritions Ltd is listed on NSE (WALPAR) and BSE ({bse}). Its next quarterly results are expected on August 2024 (Q1 FY25).
Cash Earnings Per Share (Cash EPS)
